Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    Presentations from the 23rd Congress of EHA 

    EHA 2018 Réa

    TFR - a new treatment goal of CP-CML patients?
    Dr Delphine Réa, Centre-Hospitalo-Universitaire Saint-Louis, Paris, France 

    • Lessons from clinical trials: TKI discontinuation in CP-CML is feasible
    • Deep-molecular responses: definitions
    • Clinical practice: patient case
    • Deep-molecular responses during 1st line TKI treatment
    • TKI discontinuation in CP-CML: transition from trials to standard practice
    • TKI withdrawal syndrome during the treatment-free phase
    • Recommendations for standard practice: definitions and management of relapses
    • Conclusion 1: Evolving treatment goals
    • Conclusion 2: TKI discontinuation in standard practice

    We are very grateful for the support of Brandcast media to produce these webstreams.